Lumateperone for Apathy in Psychotic Disorders
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a medication called lumateperone to see if it can improve apathy (lack of motivation) in people who have psychotic symptoms from schizophrenia or related disorders. It may help if you are already on a stable treatment but still struggle with apathy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with schizophrenia, schizoaffective disorder, or another psychotic disorder.
- You have significant apathy or lack of motivation (measured by a standard questionnaire).
- If you take medication for your condition, the dose has been stable for at least 30 days.
- You are not currently taking more than one antipsychotic medicine or a long-acting antipsychotic injection.
- You do not have dementia, Parkinson's disease, or a substance use disorder (except tobacco).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding lumateperone, an antipsychotic medication, to clozapine can improve metabolic health in people with schizophrenia. It aims to see if this combination helps with weight, blood sugar, and cholesterol levels.
This trial tests a medication called lumateperone for children and teens with schizophrenia, bipolar disorder, or autism spectrum disorder. It aims to see if the medicine is safe and tolerable over time.
This study looks at “apathy,” or reduced motivation/interest, in people with schizophrenia or depression. It may help researchers understand what drives apathy and how to measure it in a clearer, more complete way.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
This study tests whether methylphenidate can reduce apathy (lack of motivation) in people with Parkinson’s disease. It may help if apathy has been persistent for weeks and your Parkinson’s medicines have been stable.
This trial tests a new drug called IRL757 to see if it is safe and helps with apathy (loss of motivation or interest) in people with Parkinson's disease. You need to have at least moderate apathy and a caregiver who can come to visits with you.
Hear when a new Apathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.